Anxiety Disorder Types From a Metabolomics Perspective: A Mendelian Randomization Analysis Based on 1400 Plasma Metabolites
Brain and Behavior · 2026-04 · 16 (4)
DOI: 10.1002/brb3.71356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, online erschienen am 29.03.2026. Verfasst von Zhen Xiao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Anxiety Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Different anxiety types demonstrate overlapping clinical features while retaining distinct characteristics, often leading to diagnostic challenges. Existing diagnostic approaches predominantly rely on symptom‐based criteria, which may result in ambiguity. The identification of biomarkers is essential for elucidating the metabolomic mechanisms underlying anxiety, thereby informing improved diagnostic and therapeutic strategies.
Methods
We conducted a Mendelian randomization (MR) study, utilizing data from genome‐wide association studies (GWAS) on plasma metabolites and three anxiety types. The study meticulously evaluated instrumental variable, as well as heterogeneity, horizontal pleiotropy, and directionality, supplemented by sensitivity analyses.
Results
Initial MR analysis identified common risk metabolites across the three anxiety subtypes. Subsequent sensitivity analyses revealed five specific generalized anxiety disorder (GAD) risk markers, including 3‐hydroxy‐2‐ethylpropionate (OR = 1.248, P IVW = 0.012) and the glutarate (C5‐DC) to salicylate ratio (OR = 1.314, P IVW = 0.007). Among social anxiety disorder (SAD) risk markers, 5‐hydroxyhexanoate (OR = 1.005, P IVW = 0.010) was unique. Potential panic disorder (PD) risk metabolites were identified as arabitol/xylitol (OR = 1.002, P IVW = 0.011), 2‐hydroxy‐3‐methylvalerate (OR = 1.002, P IVW = 0.008), and the AMP to phosphate ratio (OR = 1.003, P IVW = 0.004). Protective factors for GAD included X‐17354 (OR = 0.739, P IVW = 0.023) and the salicylate to citrate ratio (OR = 0.754, P IVW = 0.010).
Conclusion
This study highlights potential metabolomic pathways involved in the shared and distinct clinical features of GAD, SAD, and PD. These findings suggest novel biomarkers for developing targeted treatments for anxiety disorders.This study investigates the causal relationship between plasma metabolites and three common types of anxiety disorders using MR analysis. Our findings propose a novel direction for utilizing metabolites as biomarkers in the diagnosis and treatment of anxiety disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, China.
- Taizhou Fifth People's Hospital, Taizhou, China.
- School of Psychology, Nanjing Normal University, Nanjing, China.
- Cognitive Behavioral Therapy Institute of Nanjing Medical University, Nanjing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xiao, Z., Wu, Z., Chen, Z., Xu, Z., Zhou, Q., Liu, S., Wang, M., Hou, S., Liu, W., Li, Z., Xun, K., Zhang, N., & Wang, C. (2026). Anxiety Disorder Types From a Metabolomics Perspective: A Mendelian Randomization Analysis Based on 1400 Plasma Metabolites. Brain and Behavior, 16(4). https://doi.org/10.1002/brb3.71356
Vancouver
Xiao Z, Wu Z, Chen Z, Xu Z, Zhou Q, Liu S, et al. Anxiety Disorder Types From a Metabolomics Perspective: A Mendelian Randomization Analysis Based on 1400 Plasma Metabolites. Brain and Behavior. 2026;16(4). doi:10.1002/brb3.71356
BibTeX
@article{Xiao2026,
author = {Xiao, Zhen and Wu, Zedi and Chen, Zixin and Xu, Ziyue and Zhou, Qi and Liu, Silan and Wang, Muqing and Hou, Shujun and Liu, Wanling and Li, Zhengyi and Xun, Kunping and Zhang, Ning and Wang, Chun},
title = {Anxiety Disorder Types From a Metabolomics Perspective: A Mendelian Randomization Analysis Based on 1400 Plasma Metabolites},
journal = {Brain and Behavior},
year = {2026},
volume = {16},
number = {4},
doi = {10.1002/brb3.71356}
}
EUVIMED